Table 1 Expression of MCT1, MCT4 and CD147 in EC tumours and their correlation with clinico–pathological characteristics
From: Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer
MCT1 (N = 89) | MCT4 (N = 87) | CD147 (N = 87) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
N = 90 (%) | Low (<200) N = 48 (53.9%) | High (≥200) N = 41 (46.1%) | p | Low (<200) N = 59 (67.8%) | High (≥200) N = 28 (32.2%) | p | Low (<200) N = 31 (35.6%) | High (≥200) N = 56 (64.4%) | p | |
Age of Onset (Median, IQR years) | 67 (57.7–74) | 69 (58.2–74.7) | 67 (56–73) | 0.917 | 67 (56–74) | 69.5 (61.5–75.2) | 0.760 | 67 (61–73) | 68 (56–75) | 0.836 |
BMI (Median) | 29.4 (26–37.8) | 29 (26.1–35.1) | 39 (26–39.5) | 0.764 | 30.7 (26–39.4) | 28 (26.2–34.9) | 0.596 | 28.2 (23.2–34.9) | 30.2 (26.3–39.5) | 0.557 |
Diabetic, N (%) | 0.094 | 0.949 | 0.678 | |||||||
Yes (0) | 71 (78.9%) | 41 (58.6%) | 29 (41.4%) | 46 (67.6%) | 22 (32.4%) | 25 (36.8%) | 43 (63.2%) | |||
No (1) | 19 (21.1%) | 7 (36.8%) | 12 (63.2%) | 13 (68.4%) | 6 (31.6%) | 6 (31.6%) | 13 (68.4%) | |||
Grade, N (%) | 0.218 | 0.313 | 0.737 | |||||||
I/II | 42 (46.7%) | 25 (60.9%) | 16 (39.1%) | 30 (73.1%) | 11 (26.9%) | 15 (37.5%) | 25 (62.5%) | |||
III | 48 (53.3%) | 23 (47.9%) | 25 (52.1%) | 29 (63.1%) | 17 (36.9%) | 16 (34.1%) | 31 (65.9%) | |||
Histological Type, N (%) | 0.614 | 0.409 | 0.988 | |||||||
Endometrioid (1) | 47 (52.2%) | 26 (56.5%) | 20 (43.5%) | 26 (56.5%) | 20 (43.5%) | 16 (35.6%) | 29 (64.4%) | |||
aNon–endometrioid (2) | 43 (47.8%) | 22 (51.2%) | 21 (48.8%) | 22 (51.2%) | 21 (48.8%) | 15 (35.7%) | 27 (64.3%) | |||
FIGO 2009 Stage, N (%) | 0.752 | 0.988 | 0.026 | |||||||
I | 58 (64.4%) | 31 (54.4%) | 26 (45.6%) | 37 (66.1%) | 19 (33.9%) | 25 (44.6%) | 31 (55.4%) | |||
II | 11 (12.2%) | 5 (45.5%) | 6 (54.5%) | 9 (81.8% | 2 (18.2%) | 2 (18.2%) | 9 (81.8%) | |||
III | 19 (21.1%) | 10 (52.6%) | 9 (47.4%) | 12 (66.7%) | 6 (33.3%) | 4 (22.2%) | 14 (77.8%) | |||
IV | 2 (2.2%) | 2 (100%) | 0 (0%) | 1 (50.0%) | 1 (50.0%) | 0 (0%) | 2 (100%) | |||
Tumour Size, N (%) | 0.234 | 0.866 | 0.117 | |||||||
Less than 2 cm (1) | 9 (10.0%) | 5 (55.6%) | 4 (44.4%) | 7 (77.8%) | 2 (22.2%) | 4 (50.0%) | 4 (50.0%) | |||
2–5 cm (2) | 46 (51.1%) | 28 (62.2%) | 17 (37.8%) | 32 (71.1%) | 13 (28.9%) | 19 (43.2%) | 25 (56.8%) | |||
Bigger than 5 cm (3) | 11 (26.7%) | 10 (41.7%) | 14 (58.3%) | 16 (72.7%) | 6 (27.3%) | 6 (25.0%) | 18 (75.0%) | |||
Missing | 24 (26.7%) | |||||||||
LVSI, N (%) | 0.928 | 0.692 | 0.948 | |||||||
No (0) | 50 (55.6%) | 26 (53.1%) | 23 (46.6%) | 33 (67.3%) | 16 (32.7%) | 17 (35.4%) | 31 (64.6%) | |||
Yes (1) | 37 (41.1%) | 20 (54.1%) | 17 (45.9%) | 25 (71.4%) | 10 (28.6%) | 13 (36.1%) | 23 (63.9%) | |||
Missing | 3 (3.3%) | |||||||||
Depth of Myometrial Invasion, N (%) | 0.680 | 0.203 | 0.512 | |||||||
Less than (<) 50% | 50 (55.6%) | 26 (52.0%) | 24 (48.0%) | 36 (73.5%) | 13 (26.5%) | 16 (32.7%) | 33 (67.3%) | |||
More than or equal to (≥) 50% | 40 (44.4%) | 22 (56.4%) | 17 (43.6%) | 23 (60.5%) | 15 (39.5%) | 15 (39.5%) | 23 (60.5%) | |||